245 related articles for article (PubMed ID: 9806393)
41. A human antibody that inhibits factor IX/IXa function potently inhibits arterial thrombosis without increasing bleeding.
Refino CJ; Jeet S; DeGuzman L; Bunting S; Kirchhofer D
Arterioscler Thromb Vasc Biol; 2002 Mar; 22(3):517-22. PubMed ID: 11884300
[TBL] [Abstract][Full Text] [Related]
42. Fragmin (LMWH) vs heparin for anticoagulation during in vitro recycling of human blood in cardiopulmonary bypass circuits: dose-dependence and mechanisms of clotting.
Bagge L; Holmer E; Wahlberg T; Nyström SO; Tydén H
Blood Coagul Fibrinolysis; 1994 Apr; 5(2):273-80. PubMed ID: 8054461
[TBL] [Abstract][Full Text] [Related]
43. New anticoagulants: current status and future potential.
Weitz JI; Crowther MA
Am J Cardiovasc Drugs; 2003; 3(3):201-9. PubMed ID: 14727932
[TBL] [Abstract][Full Text] [Related]
44. Activation of the coagulation mechanism on tumor necrosis factor-stimulated cultured endothelial cells and their extracellular matrix. The role of flow and factor IX/IXa.
Tijburg PN; Ryan J; Stern DM; Wollitzky B; Rimon S; Rimon A; Handley D; Nawroth P; Sixma JJ; de Groot PG
J Biol Chem; 1991 Jun; 266(18):12067-74. PubMed ID: 2050700
[TBL] [Abstract][Full Text] [Related]
45. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass.
Boisclair MD; Lane DA; Philippou H; Esnouf MP; Sheikh S; Hunt B; Smith KJ
Blood; 1993 Dec; 82(11):3350-7. PubMed ID: 8241505
[TBL] [Abstract][Full Text] [Related]
46. Factor IXa as a target for anticoagulation in thrombotic disorders and conditions.
Smiley DA; Becker RC
Drug Discov Today; 2014 Sep; 19(9):1445-53. PubMed ID: 24998782
[TBL] [Abstract][Full Text] [Related]
47. [Principles of the treatment of hypercoagulabilities with a rational anticoagulant therapy].
Raby C
Presse Med (1893); 1969 Jan; 77(1):17-9. PubMed ID: 5785756
[No Abstract] [Full Text] [Related]
48. Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery.
Chomiak PN; Walenga JM; Koza MJ; Reilly TM; Turlapathy P; Pifarre R
Circulation; 1993 Nov; 88(5 Pt 2):II407-12. PubMed ID: 7993389
[TBL] [Abstract][Full Text] [Related]
49. Haemostasis at low heparin dosage during cardiopulmonary bypass with heparin-coated circuits in pigs.
Bagge L; Borowiec JW; Thelin S; Hultman J
Scand Cardiovasc J; 1997; 31(5):275-81. PubMed ID: 9406294
[TBL] [Abstract][Full Text] [Related]
50. Antithrombin supplementation attenuates heparin resistance in plasma spiked with Gla-domainless factor Xa S195A in vitro.
Mishima Y; Butt AL; Vandyck KB; Levy JH; Stewart KE; Tanaka KA
Br J Anaesth; 2024 Jun; 132(6):1204-1210. PubMed ID: 38594117
[TBL] [Abstract][Full Text] [Related]
51. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
Westmark PR; Tanratana P; Sheehan JP
J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
[TBL] [Abstract][Full Text] [Related]
52. Effects of hemodilution, blood loss, and consumption on hemostatic factor levels during cardiopulmonary bypass.
Chandler WL
J Cardiothorac Vasc Anesth; 2005 Aug; 19(4):459-67. PubMed ID: 16085250
[TBL] [Abstract][Full Text] [Related]
53. Factor V Leiden and Cardiopulmonary Bypass.
Uppal V; Rosin M; Marcoux JA; Olson M; Bezaire J; Dalshaug G
J Extra Corpor Technol; 2015 Dec; 47(4):223-7. PubMed ID: 26834284
[TBL] [Abstract][Full Text] [Related]
54. Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.
Griffith MJ; Breitkreutz L; Trapp H; Briet E; Noyes CM; Lundblad RL; Roberts HR
J Clin Invest; 1985 Jan; 75(1):4-10. PubMed ID: 3871202
[TBL] [Abstract][Full Text] [Related]
55. Practical approach to anticoagulation for cardiopulmonary bypass in the patient with congenital prolonged activated partial thromboplastin time.
Cankovic L; Steenwyk BL; McGiffin DC; Nielsen VG
Blood Coagul Fibrinolysis; 2008 Oct; 19(7):725-6. PubMed ID: 18832918
[TBL] [Abstract][Full Text] [Related]
56. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
[TBL] [Abstract][Full Text] [Related]
57. Con: The Hepcon HMS Should Not Be Used Instead of Traditional Activated Clotting Time to Dose Heparin and Protamine for Cardiac Surgery Requiring Cardiopulmonary Bypass.
Gilly G; Trusheim J
J Cardiothorac Vasc Anesth; 2016 Dec; 30(6):1730-1732. PubMed ID: 27751763
[No Abstract] [Full Text] [Related]
58. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer.
Young JA; Kisker CT; Doty DB
Ann Thorac Surg; 1978 Sep; 26(3):231-40. PubMed ID: 110273
[TBL] [Abstract][Full Text] [Related]
59. Anticoagulation management associated with extracorporeal circulation.
Sniecinski RM; Levy JH
Best Pract Res Clin Anaesthesiol; 2015 Jun; 29(2):189-202. PubMed ID: 26060030
[TBL] [Abstract][Full Text] [Related]
60. Effect of hirudin versus heparin on hemocompatibility of blood contacting biomaterials: an in vitro study.
Kopp R; Bernsberg R; Kashefi A; Mottaghy K; Rossaint R; Kuhlen R
Int J Artif Organs; 2005 Dec; 28(12):1272-7. PubMed ID: 16404704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
